(Q35165726)

6 August 2017

1 reference

title

Cancer gene therapy: an awkward adolescence (English)

1 reference

6 August 2017

0 references

0 references

1 reference

Michael M Gottesman

1

1 reference

6 August 2017

publication date

1 July 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

10

1 reference

6 August 2017

issue

7

1 reference

6 August 2017

page(s)

501-508

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700602

6 August 2017

exact match

0 references

cites work

Selection of gene-marked tumor infiltrating lymphocytes from post-treatment biopsies: a case study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

MDA-7/IL-24: novel cancer growth suppressing and apoptosis inducing cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Retroviral gene transfer of dominant negative raf-1 mutants suppresses ha-ras-induced transformation and delays tumor formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Apoptosis-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Replication-selective viruses for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Selectively replicating adenoviruses for oncolytic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

A novel, helper-dependent, adenovirus-retrovirus hybrid vector: stable transduction by a two-stage mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Transcription-targeted gene therapy for androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Multidrug resistance in cancer: role of ATP-dependent transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Gene therapy death prompts review of adenovirus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Development of lentiviral vectors for antiangiogenic gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Herpes simplex virus vectors for the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

In vitro-packaged SV40 pseudovirions as highly efficient vectors for gene transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Tumor gene therapy by MVA-mediated expression of T-cell-stimulating antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Improved DNA: liposome complexes for increased systemic delivery and gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

7 January 2021

Apoptosis and cancer: when BAX is TRAILing away

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

7 January 2021

Immunotherapy of metastasis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

1 reference

7 January 2021

Gene therapy of severe combined immunodeficiencies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700602

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700602

1 reference

6 August 2017

1 reference